Adicet Bio, Inc.
0HX7.L
London Stock Exchange8.84
USD
-0.63
- -
Adicet Bio, Inc.
0HX7.L
(London Stock Exchange)
Recent
price
8.84
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Adicet Bio, Inc. is a clinical-stage biotechnology firm dedicated to advancing innovative allogeneic gamma delta T cell immunotherapies for the potential treatment of both cancers and autoimmune conditions. The company leverages its proprietary platform to create "off-the-shelf" T cell products, incorporating chimeric antigen receptors to enhance precise targeting, bolster innate and adaptive anti-disease immune responses, and promote sustained activity in patients. Its primary investigational candidate, ADI-001, an allogeneic anti-CD20 CAR gamma delta T cell therapy, is currently undergoing Phase 1 clinical evaluation for relapsed or refractory B-cell non-Hodgkin's lymphoma. Furthermore, ADI-001 is being investigated in a broad Phase 1 clinical trial for autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, anti-neutrophil cytoplasmic autoantibody associated vasculitis, and rheumatoid arthritis. Recent preliminary data from autoimmune disease cohorts have demonstrated positive safety and efficacy, leading to Fast Track Designations by the FDA for several of these indications. The company is strategically advancing ADI-212, a gene-edited and cytokine-armored next-generation clinical candidate designed to target prostate-specific membrane antigen (PSMA) in solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.